Drug Trial Radar · NCT01134055
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Jan 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
Jun 1, 2010
Primary completion
Oct 1, 2012
Study completion Oct 1, 2012
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
Conditions
- Macular Degeneration
Interventions
pazopanib eye dropsDrug
A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
placeboDrug
placebo eye drops
ranibizumab intravitreal injectionBiological
Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52Time frame: Day 1 and 52 weeks
Locations
77 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Peoria, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Irvine, California
GSK Investigational Site
Loma Linda, California
GSK Investigational Site
Poway, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Golden, Colorado
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Winter Haven, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Leawood, Kansas
GSK Investigational Site
Paducah, Kentucky
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Royal Oak, Michigan
GSK Investigational Site
Traverse City, Michigan
GSK Investigational Site
New York, New York
GSK Investigational Site
Asheville, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Beachwood, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Ashland, Oregon
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Salt Lake City, Utah
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Silverdale, Washington
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.